Integrating Biosimilars into Supportive Care: Insights for Informed Decisions

Biosimilars, which have been available in Europe for more than 10 years, are increasingly gaining regulatory approval in the United States. These agents have the potential to contain rapidly increasing health care costs and simultaneously enable greater patient access. The cornerstone of broad acceptance of biosimilars is increased education of all involved parties regarding regulatory standards for biosimilar approval, preclinical and clinical data requirements, interchangeability, and extrapolation of indications.


This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with cancer.


Upon completion of this activity, participants will be better able to do the following:

  1. Define biosimilar concepts such as totality of evidence, extrapolation of indications, and interchangeability, and discuss the current approach to establish the safety and efficacy of biosimilars
  2. Describe risk factors for febrile neutropenia and appropriate risk-based implementation of granulocyte colony stimulating factor (G-CSF) in patients with cancer undergoing chemotherapy
  3. Assess anemia risk and initiate erythropoietic-stimulating agents when indicated
  4. Identify strategies to overcome potential practical challenges of incorporating biosimilars into clinical practice


Lee S. Schwartzberg, MD, FACP
(Program Chair)

Division of Hematology & Oncology
The University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee

Jeffrey Crawford, MD
Professor of Medicine
Duke Cancer Institute
Durham, North Carolina

Robert M. Rifkin, MD, FACP
Clinical Associate Professor of Medicine
University of Colorado School of Medicine
Denver, Colorado
Attending Physician
Rocky Mountain Cancer Centers
Denver, Colorado

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:

Lee S. Schwartzberg, MD, FACP

Has no relationships with commercial interests.

Jeffrey Crawford, MD

Consultant/Advisor: AstraZeneca; Celgene Corporation; Dova Pharmaceuticals; F. Hoffmann-La Roche Ltd; G1 Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co.; Inc., Merrimack; Mylan N.V.; Pfizer Inc.

Grant/Research Support: Amgen Inc; AstraZeneca; Bayer AG; Genentech, Inc.

Robert M. Rifkin, MD, FACP

Consultant/Advisor: Amgen Inc; Coherus Biosciences; EMD Serono, Inc.; Hospira; Mylan N.V.; Pfizer Inc.

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Sandoz Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Sandoz Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.